Related references
Note: Only part of the references are listed.Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction
Jasper W. L. Hartog et al.
EUROPEAN JOURNAL OF HEART FAILURE (2010)
Tumor necrosis factor-α produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload
Yuanwen Chen et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes
Lin Lu et al.
ATHEROSCLEROSIS (2009)
Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients
Xiao Xiang Yan et al.
ATHEROSCLEROSIS (2009)
Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling
Takashi Kohno et al.
CARDIOVASCULAR RESEARCH (2009)
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Stephane Heymans et al.
EUROPEAN JOURNAL OF HEART FAILURE (2009)
RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation
Louis J. Sparvero et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications
Giuseppina Basta
ATHEROSCLEROSIS (2008)
High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice
Tatsuro Kitahara et al.
CARDIOVASCULAR RESEARCH (2008)
High-mobility group box-1 in ischemia-reperfusion injury of the heart
Martin Andrassy et al.
CIRCULATION (2008)
Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart
Kunihiko Takahashi et al.
CIRCULATION (2008)
A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)
Angela Raucci et al.
FASEB JOURNAL (2008)
Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure
Yo Koyama et al.
JOURNAL OF CARDIAC FAILURE (2008)
Clinical and prognostic value of advanced glycation end-products in chronic heart failure
Jasper W. L. Hartog et al.
EUROPEAN HEART JOURNAL (2007)
High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure
Yo Koyama et al.
JOURNAL OF CARDIAC FAILURE (2007)
Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein
Annalisa Porto et al.
FASEB JOURNAL (2006)
Advanced glycation end products - Sparking the development of diabetic vascular injury
Alison Goldin et al.
CIRCULATION (2006)
Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac c-kit+ cell proliferation and differentiation
F Limana et al.
CIRCULATION RESEARCH (2005)
Inflammatory dilated cardiomyopathy (DCMI)
B Maisch et al.
HERZ (2005)
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation
R Palumbo et al.
JOURNAL OF CELL BIOLOGY (2004)
Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions - Role of activated macrophages and cytokines
N Kalinina et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes
D Aronson
JOURNAL OF HYPERTENSION (2003)
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
P Scaffidi et al.
NATURE (2002)
Advanced glycation end products and endothelial dysfunction in type 2 diabetes
KCB Tan et al.
DIABETES CARE (2002)
Advanced glycation end products in nondiabetic patients with coronary artery disease
M Kanauchi et al.
DIABETES CARE (2001)
Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients
K Kiuchi et al.
HEART (2001)
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes
U Andersson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness
M Asif et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)